- Home
- DMLP vs KLRA Comparison
DMLP vs KLRA Comparison
Compare DMLP & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMLP | KLRA |
|---|---|---|
| Founded | 2003 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2002 | 2026 |
Fundamental Metrics
Financial Performance| Metric | DMLP | KLRA |
|---|---|---|
| Price | $27.53 | $13.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.75 |
| AVG Volume (30 Days) | 83.8K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 10.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $152,832,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.85 | $9.76 |
| 52 Week High | $31.08 | $23.82 |
Technical Indicators
Market Signals| Indicator | DMLP | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 54.48 |
| Support Level | $26.43 | $9.76 |
| Resistance Level | $28.39 | $13.83 |
| Average True Range (ATR) | 0.77 | 0.90 |
| MACD | -0.38 | 0.09 |
| Stochastic Oscillator | 5.23 | 72.08 |
Price Performance
Historical ComparisonAbout DMLP Dorchester Minerals L.P.
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonuses, and others.
About KLRA Kailera Therapeutics Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.